Breaking News Instant updates and real-time market news.

AMRN

Amarin

$3.10

-0.06 (-1.90%)

05:44
04/12/18
04/12
05:44
04/12/18
05:44

Amarin presents two posters about Vascepa at the National Kidney Foundation

Amarin announced the presentation of two posters this week at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX, April 10-14, 2018. These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein, or hsCRP, levels, and persistent high triglycerides, or TG, despite statin therapy due to the association with increased cardiovascular disease, or CVD, risk. The poster titled "Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Persistent High Triglycerides, eGFR less than90 mL/min/1.73 m2, and Diabetes Mellitus" showed that, consistent with overall ANCHOR study results, compared with placebo, icosapent ethyl, or IPE, 4g/day significantly decreased the primary endpoint of triglycerides, or TG, and other lipids without increasing LDL-C. Apolipoproteins and markers of oxidation and inflammation were significantly improved.

AMRN Amarin
$3.10

-0.06 (-1.90%)

04/09/18
JEFF
04/09/18
NO CHANGE
Target $7
JEFF
Buy
Amarin risk/reward favorable into Q3 data, says Jefferies
Jefferies analyst Matthew Andrews surveyed 50 U.S. physicians and high prescribers of Amarin's Vascepa to assess current use of Vascepa in mixed dyslipidemia and severe high triglycerides, and future prescribing habits based on the REDUCE-IT data. The survey indicates Vascepa is the leading triglycerides-lowering drug in severe hypertriglyceridemia and mixed dyslipidemia, and positive MACE data in the REDUCE-IT trial could increase use 125% and 50%, respectively, Andrews tells investors in a research note. The analyst estimates peak-adjusted U.S. Vascepa sales of $1.06B by 2030. He sees a favorable risk/reward on Amarin shares into the Q3 data. The stock has upside to $7 on positive data and downside to $2.25 on a negative readout, Andrews contends. He keeps a Buy rating on Amarin with a $7 price target.
03/01/18
HCWC
03/01/18
NO CHANGE
Target $10
HCWC
Buy
Amarin has 'significant upside' on positive trial data, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein continues to believe that Amarin's current valuation is supported by Vascepa sales alone. The potential success of the Reduce-It trial represents "significant upside," Fein tells investors in a research note. He reiterates a Buy rating on Amarin with a $10 price target following the company's Q4 results.
02/20/18
CANT
02/20/18
NO CHANGE
Target $10
CANT
Overweight
Amarin shares compelling ahead of data, Cantor Fitzgerald
Amarin shares represent a "compelling investment opportunity" ahead of data for the company's Reduce-It study before the end of Q3, Cantor Fitzgerald analyst Louise Chen wrote Friday in a research note to investors. She expects the data to be positive. Amarin recently raised $70M and could raise up to another $10.5M gross, if overallotment is exercised, ahead of the data readout which removes a financing overhang and accelerates the company's plan to expand its sales and promotion of Vascepa, Chen argues. She keeps an Overweight rating on the shares with a $10 price target.
01/23/18
CANT
01/23/18
NO CHANGE
Target $10
CANT
Overweight
Amarin shares have room to run ahead of data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen views this morning's announcement from Amarin as good news since the company is on track to report top-line results from the study before the end of Q3. Amarin this morning announced that its Reduce-It cardiovascular outcomes study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events. The analyst believes the shares have to room to run ahead of the data release. She keeps an Overweight rating on the name with a $10 price target.

TODAY'S FREE FLY STORIES

BMWYY

BMW

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Periodicals
Trump plans talks with German car executives, Bloomberg says »

The White House has…

BMWYY

BMW

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.91

-0.535 (-2.10%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Options
Gap options imply 11.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

D

Dominion

$74.65

0.25 (0.34%)

, SCG

Scana

$44.08

0.38 (0.87%)

15:01
11/20/18
11/20
15:01
11/20/18
15:01
Periodicals
Dominion proposes alternate plan for Scana deal, Bloomberg says »

Bloomberg cites an…

D

Dominion

$74.65

0.25 (0.34%)

SCG

Scana

$44.08

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$11.27

-0.865 (-7.13%)

15:00
11/20/18
11/20
15:00
11/20/18
15:00
Options
Active trading in US Oil Fund options as crude oil drops 7% »

Active trading in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
11/20/18
11/20
15:00
11/20/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:56
11/20/18
11/20
14:56
11/20/18
14:56
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Durable Goods Preview »

U.S. Durable Goods…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Existing Home Sales Preview »

U.S. Existing Home Sales…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Michigan Consumer Sentiment Preview »

U.S. Michigan Consumer…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Leading Indicators Preview »

U.S. Leading Indicators…

FB

Facebook

$131.60

-0.02 (-0.02%)

14:53
11/20/18
11/20
14:53
11/20/18
14:53
Periodicals
Dashboard to track time wasted on Facebook starts roll out, Venture Beat says »

Facebook has confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:52
11/20/18
11/20
14:52
11/20/18
14:52
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

XRT

S&P Retail Index SPDR

$44.32

-1.2 (-2.64%)

14:50
11/20/18
11/20
14:50
11/20/18
14:50
Options
SPDR Retail Trust options are active ahead of Black Friday »

SPDR Retail Trust options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$122.41

-3.34 (-2.66%)

14:49
11/20/18
11/20
14:49
11/20/18
14:49
Options
Autodesk options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

  • 04

    Dec

EQT

EQT Corporation

$16.81

-0.25 (-1.47%)

14:45
11/20/18
11/20
14:45
11/20/18
14:45
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.78

-0.635 (-3.87%)

14:35
11/20/18
11/20
14:35
11/20/18
14:35
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDX

Celldex

$0.31

-0.0002 (-0.06%)

14:32
11/20/18
11/20
14:32
11/20/18
14:32
Hot Stocks
Celldex announces launch of Chase Offers »

Cardlytics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

, VLKAY

Volkswagen

$0.00

(0.00%)

14:32
11/20/18
11/20
14:32
11/20/18
14:32
Periodicals
Trump plans talks with German car executives, Bloomberg says »

German carmakers include…

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAMXY

BMW Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$33.87

-0.75 (-2.17%)

14:31
11/20/18
11/20
14:31
11/20/18
14:31
Hot Stocks
Mylan says has discontinued a number of products from Morgantown site »

Mylan commented on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

NAVI

Navient

$11.20

-0.79 (-6.59%)

14:31
11/20/18
11/20
14:31
11/20/18
14:31
Periodicals
DOE audit in 2017 found deceptive practices at Navient, AP reports »

A 2017 audit done by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NAVI

Navient

$11.45

-0.54 (-4.50%)

14:27
11/20/18
11/20
14:27
11/20/18
14:27
Hot Stocks
Breaking Hot Stocks news story on Navient »

Navient down 8% to $11.06…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NAVI

Navient

$11.45

-0.54 (-4.50%)

14:26
11/20/18
11/20
14:26
11/20/18
14:26
Periodicals
Breaking Periodicals news story on Navient »

DOE audit found deceptive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

14:25
11/20/18
11/20
14:25
11/20/18
14:25
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss the U.S.…

ROST

Ross Stores

$84.39

-6.8 (-7.46%)

14:24
11/20/18
11/20
14:24
11/20/18
14:24
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SPCB

SuperCom

$1.29

-0.05 (-3.73%)

14:20
11/20/18
11/20
14:20
11/20/18
14:20
Hot Stocks
SuperCom CEO acquires 365,000 ordinary shares »

SuperCom announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.